Should we recommend universal aspirin for all pregnant women?

American Journal of Obstetrics and Gynecology

Volumn 216, Issue 2, 2017, Pages 141.e1-141.e5

  Mone, Fionnuala ^a   Mulcahy, Cecilia ^a   McParland, Peter ^a,b   McAuliffe, Fionnuala M ^a,b  

^a NATIONAL MATERNITY HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

fetal growth restriction; low dose aspirin; preeclampsia; universal

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ARTICLE; BRAIN HEMORRHAGE; CONGENITAL MALFORMATION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; GASTROSCHISIS; HIGH RISK POPULATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; NEONATAL HEMORRHAGE; PATIENT ATTITUDE; PATIENT COMPLIANCE; POSTPARTUM HEMORRHAGE; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; VAGINA BLEEDING; BLOOD PRESSURE; DIAGNOSTIC IMAGING; DRUG RESISTANCE; FETAL GROWTH RETARDATION; MEDICATION COMPLIANCE; METABOLISM; PRACTICE GUIDELINE; PRE-ECLAMPSIA; PREGNANCY; PULSATILE FLOW; RISK ASSESSMENT; UTERINE ARTERY;

ASPIRIN; BLOOD PRESSURE; DRUG RESISTANCE; FEMALE; FETAL GROWTH RETARDATION; HUMANS; MEDICATION ADHERENCE; PATIENT ACCEPTANCE OF HEALTH CARE; PLACENTA GROWTH FACTOR; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PULSATILE FLOW; RISK ASSESSMENT; UTERINE ARTERY;

EID: 85010876778     PISSN: 00029378     EISSN: 10976868     Source Type: Journal    
DOI: 10.1016/j.ajog.2016.09.086     Document Type: Article

References (32)

1. 1 Oliveira, N., Magder, L.S., Blitzer, M.G., Baschat, A.A., First-trimester prediction of pre-eclampsia: external validity of algorithms in a prospectively enrolled cohort. Ultrasound Obstet Gynecol 44 (2014), 279–285.
2. 2 Vainio, M., Maenpaa, J., Riutta, A., et al. In the dose range of 0.5-2.0 mg/kg acetylsalicylic acid does not affect prostacyclin production in hypertensive pregnancies. Acta Obstet Gynaecol Scand 78 (1999), 82–88.
3. 3 American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy: report of the American College of Obstetricians and Gynecologists Task Force on hypertension in pregnancy. 2013, The College, Washington (DC), 1122–1131.
4. 4 Akolekar, R., Syngelaki, A., Poon, L., Wright, D., Nicolaides, K.H., Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 33 (2013), 8–15.
5. 5 Park, F.J., Leung, C.H.Y., Poon, L.C.Y., Williams, P.F., Rothwell, S.J., Hyett, J.A., Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease in pregnancy. Aust N Z J Obstet Gynaecol 53 (2013), 532–539.
6. 6 Henderson, J.T., Whitlock, E.P., O'Connor, E., Senger, C.A., Thompson, J.H., Rowland, M.G., Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review from the U.S. Preventative Services Task Force. Ann Intern Med 160 (2014), 695–703.
7. 7 The National Institute for Health and Clinical Excellence. The management of hypertensive disorders during pregnancy. Clinical Guideline 107; August 2010. Available at: http://www.nice.org.uk/nicemedia/live/13098/50418/50418.pdf. Accessed June 20, 2014.
8. 8 LeFevre, M.L., U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 161 (2014), 819–826.
9. 9 Poon, L.C.Y., Kametas, N.A., Cheleman, T., Leal, A., Nicolaides, K.H., Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens 24 (2010), 104–110.
10. 10 CLASP: a randomized trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 343 (1994), 619–629.
11. 11 Duley, L., Henderson-Smart, D.J., Meher, S., King, J.F., Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev, 2, 2007, CD004659.
12. 12 The Fetal Medicine Foundation. Randomized trials: ASPRE. Available at: https://fetalmedicine.org/research/randomized-trials/aspre-1. Accessed May 15, 2016.
13. 13 Di Sessa, T.G., Moretti, M.L., Khoury, A., Pulliam, D.A., Arheart, K.L., Sibai, B.M., Cardiac function in fetuses and newborns exposed to low-dose aspirin during pregnancy. Am J Obstet Gynecol 171 (1994), 892–900.
14. 14 Schiessl, B., Schneider, K.T., Zimmermann, A., Kainer, F., Friese, K., Oberhoffer, R., Prenatal constriction of the fetal ductus arteriosus-related to maternal pain medication?. Z Geburtshilfe Neonatol 209 (2005), 65–68.
15. 15 Wyatt-Ashmead, J., Antenatal closure of the ductus arteriosus and hydrops fetalis. Pediatr Dev Pathol 14 (2011), 469–474.
16. 16 Werler, M.M., Mitchell, A.A., Shapiro, S., The relation of aspirin use during the first trimester of pregnancy to congenital cardiac defects. N Engl J Med 321 (1989), 1639–1642.
17. 17 Norgard, B., Puho, E., Czeizel, A.E., Skriver, M.V., Sorensen, H.T., Aspirin use during early pregnancy and the risk of congenital abnormalities: a population-based case-control study. Am J Obstet Gynecol 192 (2005), 922–923.
18. 18 Vandermeulen, E.P., Van Aken, H., Vermylen, J., Anticoagulants and spinal-epidural anesthesia. Anesth Analg 79 (1994), 1165–1177.
19. 19 Bujold, E., Roberge, S., Lacasse, Y., et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 116 (2010), 402–414.
20. 20 Bartsch, E., Park, A.L., Kingdom, J.C., Ray, J.G., Risk threshold for starting low dose aspirin in pregnancy to prevent preeclampsia: an opportunity at a low cost. PLoS One, 10, 2015, e0116296.
21. 21 Werner, E.F., Hauspurg, A.K., Rouse, D.J., A cost-benefit analysis of low-dose aspirin prophylaxis for the prevention of preeclampsia in the United States. Obstet Gynecol 126 (2015), 1242–1250.
22. 22 Khan, K.S., Wojdyla, D., Say, L., Metin Gulmezoglu, A., Van Look, P.F.A., WHO analysis of causes of maternal death: a systematic review. Lancet 367 (2006), 1066–1074.
23. 23 Danso, K.A., Opare-Addo, H.S., Challenges associated with hypertensive disease during pregnancy in low-income countries. Int J Obstet Gynaecol 110 (2010), 78–81.
24. 24 Meads, C.A., Cnossen, J.S., Meher, S., et al. Methods of prediction and prevention of pre-eclampsia: systematic reviews of accuracy and effectiveness literature with economic modelling. Health Technol Assess 12 (2008), 1–270.
25. 25 Michelson, A.D., Platelet function testing in cardiovascular diseases. Circulation 110 (2004), e489–e493.
26. 26 Alfirevic, A., Estimating aspirin resistance in high-risk women (EARTH). NHS Health research Authority Research Summaries, 2016 Available at: http://www.hra.nhs.uk/news/research-summaries/estimating-aspirin-resistance-in-high-risk-women-earth/#sthash.viCTufxZ.dpuf Accessed June 20, 2016.
27. 27 Navaratnam, K., Alfirevic, A., Alfirevic, Z., Low dose aspirin and pregnancy: how important is aspirin resistance?. BJOG 123 (2016), 1481–1487.
28. 28 De Jonge, L., de Walle, H.E.K., de Jong-van den Berg, L.T.W., van Langen, I.M., Bakker, M.K., Actual use of medications prescribed during pregnancy: a cross-sectional study using data from a population-based congenital anomaly registry. Drug Saf 38 (2015), 737–747.
29. 29 Van Gelder, M.M.H.J., van Rooij, I.A.L.M., de Walle, H.E.K., Roeleveld, N., Bakker, M.K., Maternal recall of prescription medication use during pregnancy using a paper-based questionnaire. Drug Saf 36 (2013), 43–54.
30. 30 Kozer, E., Nikfar, S., Costei, A., Boskovic, R., Nulman, L., Koren, G., Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 187 (2002), 1623–1630.
31. 31 Schisterman, E.F., Silver, R.M., Lesher, L.L., et al. Preconception low-dose aspirin and pregnancy outcomes: results from the EAGeR randomised trial. Lancet 384 (2014), 29–36.
32. 32 Roberge, S., Giguere, Y., Villa, P., et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol 29 (2012), 551–556.